Specific (n = 1310) | NSC (n = 190) | Total (n = 1500) | p | ||||
---|---|---|---|---|---|---|---|
Sociodemographic characteristics | |||||||
Age, [med (IQR)] | 50.0 | (33–67) | 55.5 | (39–68) | 51.0 | (34–67) | 0.027 |
Sex, [n (%)] | |||||||
Female | 640 | (48.9) | 73 | (38.4) | 713 | (47.5) | |
Male | 670 | (51.1) | 117 | (61.6) | 787 | (52.5) | 0.007 |
Swiss nationality, [n (%)] | 927 | (70.8) | 142 | (74.7) | 1069 | (71.3) | 0.258 |
Private insurance, [n (%)] | 171 | (13.1) | 40 | (21.1) | 1069 | (71.3) | 0.003 |
Transport by EMS | 373 | (28.5) | 46 | (24.2) | 419 | (27.9) | 0.221 |
Time and day of admission to ED | |||||||
Saturday or Sunday admission, [n (%)] | 431 | (32.9) | 51 | (26.8) | 482 | (32.1) | 0.095 |
Night-time admissions, [n (%)] | 593 | (45.3) | 74 | (38.9) | 667 | (44.5) | 0.101 |
Effective weekendsa, [n (%)] | 519 | (39.6) | 57 | (30.0) | 576 | (38.4) | 0.011 |
Effective days offb, [n (%)] | 443 | (33.8) | 53 | (27.9) | 496 | (33.1) | 0.105 |
Comorbidity | |||||||
COPD, [n (%)] | 75 | (5.7) | 9 | (4.7) | 84 | (5.6) | 0.580 |
Diabetes, [n (%)] | 153 | (11.7) | 38 | (20.0) | 191 | (12.7) | 0.001 |
Liver disease, [n (%)] | 89 | (6.8) | 16 | (8.4) | 105 | (7.0) | 0.411 |
Dementia, [n (%)] | 27 | (2.1) | 6 | (3.2) | 33 | (2.2) | 0.335 |
Past myocardial infarction, [n (%)] | 181 | (13.8) | 20 | (10.5) | 201 | (13.4) | 0.213 |
Malignancy, [n (%)] | 204 | (15.6) | 35 | (18.4) | 239 | (15.9) | 0.316 |
Peripheral artery disease, [n (%)] | 42 | (3.2) | 4 | (2.1) | 46 | (3.1) | 0.411 |
Chronic kidney disease, [n (%)] | 51 | (3.9) | 9 | (4.7) | 60 | (4.0) | 0.579 |
Cerebrovascular disease, [n (%)] | 98 | (7.5) | 16 | (8.4) | 114 | (7.6) | 0.648 |
Drug intake | |||||||
On any antidiabetic, [n (%)] | 104 | (7.9) | 27 | (14.2) | 131 | (8.7) | 0.004 |
On any antithrombotic, [n (%)] | 372 | (28.4) | 59 | (31.1) | 431 | (28.7) | 0.450 |
On any antihypertensive, [n (%)] | 411 | (31.4) | 69 | (36.3) | 480 | (32.0) | 0.172 |
On any diuretic, [n (%)] | 178 | (13.6) | 25 | (13.2) | 203 | (13.5) | 0.871 |
On any antibiotic, [n (%)] | 188 | (14.4) | 15 | (7.9) | 203 | (13.5) | 0.015 |
On any antiepileptic, [n (%)] | 108 | (8.2) | 14 | (7.4) | 122 | (8.1) | 0.680 |
On any opioids, [n (%)] | 97 | (7.4) | 15 | (7.9) | 112 | (7.5) | 0.810 |
On any psycholeptic, [n (%)] | 178 | (13.6) | 26 | (13.7) | 204 | (13.6) | 0.971 |
Consultation characteristic | |||||||
Triage category, [med (iqr)] | 3.0 | (2, 3) | 3.0 | (2, 3) | 3.0 | (2, 3) | < 0.001 |
Highly-urgent | 588 | (44.9) | 55 | (28.9) | 643 | (42.9) | |
Urgent | 722 | (55.1) | 135 | (71.1) | 857 | (57.1) | < 0.001 |
Resuscitation bay, [n (%)] | 17 | (1.3) | 2 | (1.1) | 19 | (1.3) | 0.778 |
Outcomes | |||||||
Hospitalisation, [n (%)] | 516 | (39.4) | 72 | (37.9) | 588 | (39.2) | 0.693 |
30 d revisits, [n (%)] | 175 | (13.4) | 22 | (11.6) | 197 | (13.1) | 0.497 |
365 d revisits, [n (%)] | 476 | (36.3) | 73 | (38.4) | 549 | (36.6) | 0.577 |
LOS hospital days, [med (iqr)] | 0.3 | (0.2–3.4) | 0.3 | (0.2–3.3) | 0.3 | (0.2–3.4) | 0.940 |
LOS ED hours, [med (iqr)] | 4.7 | (3.4–6.5) | 4.9 | (3.3–6.8) | 4.7 | (3.3–6.6) | 0.871 |
ICU admission, [n (%)] | 108 | (8.2) | 13 | (6.8) | 121 | (8.1) | 0.507 |
In-hospital death, [n (%)] | 21 | (1.6) | 5 | (2.6) | 26 | (1.7) | 0.310 |